Farther Finance Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Farther Finance Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6	Closed	-$644	–	2598
2023 Q1	$644	Buy	+6	New	+$691	﹤0.01%	1943

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Farther Finance Advisors's RXDX Position: Q2 2023 in Review

Farther Finance Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 6 shares — an estimated $644 sold.

Farther Finance Advisors first reported a position in RXDX in Q1 2023 and held it in 1 quarter. The position peaked at $644 in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Farther Finance Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Farther Finance Advisors sold 6 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $644.
Farther Finance Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Farther Finance Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $644 in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Farther Finance Advisors's 13F filing for Q2 2023, filed 12 Sep 2023.